Ranked #6,995 of 8,699 institutional investors
Sarissa Capital Management LP
Greenwich, CT
$153M
US stock portfolio at live prices · today +$900K (+0.59%)
Live prices, last trade 11:09 AM ET
- Value at quarter end (Q3 2026)
- $153M
- Change from Q2 2026
- −$24.7M (−13.89%)
- Positions
- 9 · 0 new, 0 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$7.8M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesIRWD 28.8%INVA 22.9%NBIX 11.8%LNTH 11.2%AMRN 9.34%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals, Inc. | 9,188,635 | $44.1M | 28.8% | Unchanged |
| INVA Innoviva, Inc. | 1,890,604 | $35.1M | 22.9% | Unchanged |
| NBIX Neurocrine Biosciences, Inc. | 116,533 | $18.0M | 11.8% | Unchanged |
| LNTH Lantheus Holdings, Inc. | 166,919 | $17.1M | 11.2% | Unchanged |
| AMRN Amarin Corporation plc | 1,287,090 | $14.3M | 9.34% | Reduced −23% |
| CYTK Cytokinetics, Incorporated | 228,623 | $12.0M | 7.84% | Unchanged |
| REGN Regeneron Pharmaceuticals, Inc. | 4,190 | $3.9M | 2.55% | Unchanged |
| VOR Vor Biopharma Inc. | 25,399 | $498K | 0.33% | Unchanged |
| BIIB Biogen Inc. | 950 | $238K | 0.16% | Unchanged |